Bart Bergstein has a strong track record in working with life sciences companies. He is a co-founder of Forbion Capital Partners, a leading European venture capital firm. At Forbion, he invested in numerous healthcare companies and served as a non-executive director on the board of many portfolio companies. He also has operational experience, serving as CFO of Cellnovo Group SA, where he successfully executed an IPO on Euronext Paris. He started his career at ABN AMRO bank, where he initiated the life sciences team within ABN AMRO private equity, and in his last position headed the Private Equity Life Sciences Team as Managing Director Life Sciences. With his team at ABN AMRO, he built a portfolio of life sciences investments valued at EUR 100m, realizing multiple highly profitable exits. In addition to his role at ISA Pharmaceuticals, Bart holds various non-executive board positions in leading-edge life sciences companies.
Pieter van der Meijden
Pieter van der Meijden (M.Sc.) is a member of the management team of “De Hoge Dennen” Holding B.V., a family-owned investment company. At De Hoge Dennen, he is responsible for developing strategy and implementation. He also is responsible for fund investments and the coordination of operational activities. Prior to joining De Hoge Dennen, he worked as managing partner at the investment company Berk Partners (2003-2007), as Managing Director Dutch Brand at Halder Invest (later called GIMV Nederland), and as Deputy Director at NIBC. Mr. Van der Meijden studied Business Economics at Erasmus University in Rotterdam.
Hendrik Zonnenberg is Director of Investments at Multifund B.V., a privately held investment office. Prior to that he was an equity analyst at ING Investment Banking (1999-2003). Mr. Zonnenberg holds an M.Sc. in Economics from the University in Groningen.